Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Ryoo, In Geun ^a   Lee, Sang Hwan ^a   Kwak, Mi Kyoung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CYTOLOGY; DISEASES; DRUG THERAPY; MAINTENANCE; TUMORS;

ANTIOXIDANT DEFENSE SYSTEM; ATAXIA-TELANGIECTASIA MUTATED; HEMATOPOIETIC STEM CELLS; MASTER REGULATORS; MULTIDRUG RESISTANCE; NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2; REACTIVE OXYGEN SPECIES; STRESS RESISTANCE;

STEM CELLS;

REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR NRF2; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; TUMOR PROTEIN;

ATAXIA TELANGIECTASIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL RENEWAL; EMBRYONIC STEM CELL; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; DRUG RESISTANCE, NEOPLASM; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; NF-E2-RELATED FACTOR 2; REACTIVE OXYGEN SPECIES;

EID: 84949266511     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/2428153     Document Type: Review

References (170)

1. C. R. Reczek and N. S. Chandel, "ROS-dependent signal transduction, " Current Opinion in Cell Biology, vol. 33, pp. 8-13, 2015.
2. P. Storz, "Forkhead homeobox type O transcription factors in the responses to oxidative stress, " Antioxidants & Redox Signaling, vol. 14, no. 4, pp. 593-605, 2011.
3. R. S. Balaban, S. Nemoto, and T. Finkel, "Mitochondria, oxidants, and aging, " Cell, vol. 120, no. 4, pp. 483-495, 2005.
4. L. A. Sena and N. S. Chandel, "Physiological roles of mitochondrial reactive oxygen species, " Molecular Cell, vol. 48, no. 2, pp. 158-167, 2012.
5. P. T. Schumacker, "Reactive oxygen species in cancer cells: live by the sword, die by the sword, " Cancer Cell, vol. 10, no. 3, pp. 175-176, 2006.
6. S. Toyokuni, K. Okamoto, J. Yodoi, and H. Hiai, "Persistent oxidative stress in cancer, " FEBS Letters, vol. 358, no. 1, pp. 1-3, 1995.
7. L. Behrend, G. Henderson, and R. Zwacka, "Reactive oxygen species in oncogenic transformation, " Biochemical Society Transactions, vol. 31, no. 6, pp. 1441-1444, 2003.
8. E. O. Hileman, J. Liu, M. Albitar, M. J. Keating, and P. Huang, "Intrinsic oxidative stress in cancer cells: A biochemical basis for therapeutic selectivity, " Cancer Chemotherapy and Pharmacology, vol. 53, no. 3, pp. 209-219, 2004.
9. H. Pelicano, D. Carney, and P. Huang, "ROS stress in cancer cells and therapeutic implications, " Drug Resistance Updates, vol. 7, no. 2, pp. 97-110, 2004.
10. Y. Adachi, Y. Shibai, J. Mitsushita, W. H. Shang, K. Hirose, and T. Kamata, "Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6, " Oncogene, vol. 27, no. 36, pp. 4921-4932, 2008.
11. J. Mitsushita, J. D. Lambeth, and T. Kamata, "The superoxidegenerating oxidase Nox1 is functionally required for Ras oncogene transformation, " Cancer Research, vol. 64, no. 10, pp. 3580-3585, 2004.
12. O. Vafa, M. Wade, S. Kern et al., "c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability, " Molecular Cell, vol. 9, no. 5, pp. 1031-1044, 2002.
13. K. Polyak, Y. Li, H. Zhu et al., "Somatic mutations of the mitochondrial genome in human colorectal tumours, " Nature Genetics, vol. 20, no. 3, pp. 291-293, 1998.
14. D. Trachootham, J. Alexandre, and P. Huang, "Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?" Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579-591, 2009.
15. X. Shi, Y. Zhang, J. Zheng, and J. Pan, "Reactive oxygen species in cancer stem cells, " Antioxidants&Redox Signaling, vol. 16, no. 11, pp. 1215-1228, 2012.
16. T. Reya, S. J. Morrison, M. F. Clarke et al., "Stem cells, cancer, and cancer stem cells, " Nature, vol. 414, no. 6859, pp. 105-111, 2001.
17. B. S. Zhou, H. Zhang, M. Damelin, K. G. Geles, J. C. Grindley, and P. B. Dirks, "Tumour-initiating cells: challenges and opportunities for anticancer drug discovery, " Nature Reviews Drug Discovery, vol. 8, no. 10, pp. 806-823, 2009.
18. D. Bonnet and J. E. Dick, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, " Nature Medicine, vol. 3, no. 7, pp. 730-737, 1997.
19. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, "A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, " Nature, vol. 445, no. 7123, pp. 106-110, 2006.
20. S. K. Singh, C. Hawkins, I. D. Clarke et al., "Identification of human brain tumour initiating cells, " Nature, vol. 432, no. 7015, pp. 396-401, 2004.
21. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, "Prospective identification of tumorigenic breast cancer cells, " Proceedings of the National Academy of Sciences, vol. 100, no. 7, pp. 3983-3988, 2003.
22. S.-H. Chiou, M.-L. Wang, Y.-T. Chou et al., "Coexpression of Oct4 andNanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelialmesenchymal transdifferentiation, " Cancer Research, vol. 70, no. 24, pp. 10433-10444, 2010.
23. F. Yu, J. Li, H. Chen et al., "Kruppel-like factor 4 (KLF4) is required formaintenance of breast cancer stem cells and for cell migration and invasion, " Oncogene, vol. 30, no. 18, pp. 2161-2172, 2011.
24. L. Vermeulen, E. M. Felipe De Sousa, M. van der Heijden et al., "Wnt activity defines colon cancer stem cells and is regulated by the microenvironment, " Nature Cell Biology, vol. 12, no. 5, pp. 468-476, 2010.
25. C. Zhao, A. Chen, C. H. Jamieson et al., "Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia, " Nature, vol. 458, no. 7239, pp. 776-779, 2009.
26. G. Farnie and R. B. Clarke, "Mammary stem cells and breast cancer-role of Notch signalling, " Stem Cell Reviews, vol. 3, no. 2, pp. 169-175, 2007.
27. D. Ponti, "Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties, " Cancer Research, vol. 65, no. 13, pp. 5506-5511, 2005.
28. M. Dean, T. Fojo, and S. Bates, "Tumour stem cells and drug resistance, " Nature Reviews Cancer, vol. 5, no. 4, pp. 275-284, 2005.
29. C. Blanpain, M. Mohrin, P. A. Sotiropoulou, and E. Passegué, "DNA-damage response in tissue-specific and cancer stem cells, " Cell Stem Cell, vol. 8, no. 1, pp. 16-29, 2011.
30. A. A. Dayem, H. Choi, J. Kim, and S. Cho, "Role of oxidative stress in stem, cancer, and cancer stem cells, " Cancers, vol. 2, no. 2, pp. 859-884, 2010.
31. E. Lagadinou, A. Sach, K. Callahan et al., "BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells, " Cell Stem Cell, vol. 12, no. 3, pp. 329-341, 2013.
32. C. Chang, Y. Chen, S. Chou et al., "Distinct subpopulations of head and neck cancer cells with different levels of intracellular reactive oxygen species exhibit diverse stemness, proliferation, and chemosensitivity, " Cancer Research, vol. 74, no. 21, pp. 6291-6305, 2014.
33. M. M. Gottesman, T. Fojo, and S. E. Bates, "Multidrug resistance in cancer: role of ATP-dependent transporters, " Nature Reviews Cancer, vol. 2, no. 1, pp. 48-58, 2002.
34. S. Achuthan, T. R. Santhoshkumar, J. Prabhakar, S. A. Nair, and M. R. Pillai, "Drug-induced senescence generates chemoresistant stemlike cellswith lowreactive oxygen species, "TheJournal of Biological Chemistry, vol. 286, no. 43, pp. 37813-37829, 2011.
35. L. Zinzi, M. Contino, M. Cantore, E. Capparelli, M. Leopoldo, and N. A. Colabufo, "ABC transporters in CSCs membranes as a novel target for treating tumor relapse, " Frontiers in Pharmacology, vol. 5, article 163, 2014.
36. A. Hadnagy, L. Gaboury, R. Beaulieu, and D. Balicki, "SP analysis may be used to identify cancer stem cell populations, " Experimental Cell Research, vol. 312, no. 19, pp. 3701-3710, 2006.
37. C. L. Bigarella, R. Liang, and S. Ghaffari, "Stem cells and the impact of ROS signaling, " Development, vol. 141, no. 22, pp. 4206-4218, 2014.
38. P. Chaudhari, Z. Ye, and Y. Y. Jang, "Roles of reactive oxygen species in the fate of stem cells, " Antioxidants&Redox Signaling, vol. 20, no. 12, pp. 1881-1890, 2014.
39. V. A. Rafalski, E. Mancini, and A. Brunet, "Energy metabolism and energy-sensing pathways in mammalian embryonic and adult stem cell fate, " Journal of Cell Science, vol. 125, no. 23, pp. 5597-5608, 2012.
40. K. Wang, T. Zhang, Q. Dong, E. C. Nice, C. Huang, and Y. Wei, "Redox homeostasis: The linchpin in stem cell self-renewal and differentiation, " Cell Death and Disease, vol. 4, no. 3, p. e537, 2013.
41. G. Saretzki, L. Armstrong, A. Leake, and et al, "Stress defense in murine embryonic stem cells is superior to that of various differentiated murine cells, " Stem Cells, vol. 22, no. 6, pp. 962-971, 2004.
42. Y. Y. Jang andS. J. Sharkis, "A lowlevel of reactive oxygen species selects for primitive hematopoietic stemcells that may reside in the low-oxygenic niche, " Blood, vol. 110, no. 8, pp. 3056-3063, 2007.
43. S. Ghaffari, "Oxidative stress in the regulation of normal and neoplastic hematopoiesis, " Antioxidants & Redox Signaling, vol. 10, no. 11, pp. 1923-1940, 2008.
44. M. Schmelter, B. Ateghang, S. Helmig, M. Wartenberg, and H. Sauer, "Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation, " The FASEB Journal, vol. 20, no. 8, pp. 1182-1184, 2006.
45. A. Alexander, S.-L. Cai, J. Kim et al., "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 9, pp. 4153-4158, 2010.
46. C. Cosentino, D. Grieco, and V. Costanzo, "ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair, " The EMBO Journal, vol. 30, no. 3, pp. 546-555, 2011.
47. K. Ito, A. Hirao, F. Arai et al., "Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells, " Nature, vol. 431, no. 7011, pp. 997-1002, 2004.
48. K. Ito, K. Takubo, F. Arai et al., "Regulation of reactive oxygen species by Atm is essential for proper response to DNA doublestrand breaks in lymphocytes, " The Journal of Immunology, vol. 178, no. 1, pp. 103-110, 2007.
49. Y. Wang, Y. Zhou, and D. T. Graves, "FOXO transcription factors: Their clinical significance and regulation, " BioMed Research International, vol. 2014, Article ID 925350, 13 pages, 2014.
50. E. Lam, R. Francis, and M. Petkovic, "FOXO transcription factors: key regulators of cell fate, " Biochemical Society Transactions, vol. 34, no. 5, pp. 722-726, 2006.
51. K. Miyamoto, K. Y. Araki, K. Naka et al., "Foxo3a is essential for maintenance of the hematopoietic stem cell pool, " Cell Stem Cell, vol. 1, no. 1, pp. 101-112, 2007.
52. Z. Tothova, R. Kollipara, B. J. Huntly et al., "FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress, " Cell, vol. 128, no. 2, pp. 325-339, 2007.
53. S. Yalcin, X. Zhang, J. P. Luciano et al., "Foxo3 is essential for the regulation of ataxia telangiectasiamutated and oxidative stressmediated homeostasis of hematopoietic stem cells, " The Journal of Biological Chemistry, vol. 283, no. 37, pp. 25692-25705, 2008.
54. J. Paik, Z. Ding, R. Narurkar et al., "FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis, " Cell Stem Cell, vol. 5, no. 5, pp. 540-553, 2009.
55. V. M. Renault, V. A. Rafalski, A. A. Morgan et al., "FoxO3 regulates neural stem cell homeostasis, " Cell Stem Cell, vol. 5, no. 5, pp. 527-539, 2009.
56. A. Brunet, A. Bonni, M. J. Zigmond et al., "Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor, " Cell, vol. 96, no. 6, pp. 857-868, 1999.
57. A. Brunet, F. Kanai, J. Stehn, and et al, "14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport, " Journal of Cell Biology, vol. 156, no. 5, pp. 817-828, 2002.
58. M. M. Juntilla, V. D. Patil, M. Calamito, R. P. Joshi, M. J. Birnbaum, and G. A. Koretzky, "AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species, " Blood, vol. 115, no. 20, pp. 4030-4038, 2010.
59. Ö. H. Yilmaz, R. Valdez, B. K. Theisen et al., "Pten dependence distinguishes haematopoietic stem cells fromleukaemiainitiating cells, " Nature, vol. 441, no. 7092, pp. 475-482, 2006.
60. S. N. Greer, J. L. Metcalf, Y. Wang, and M. Ohh, "The updated biology of hypoxia-inducible factor, " The EMBO Journal, vol. 31, no. 11, pp. 2448-2460, 2012.
61. C. E. Forristal, K. L. Wright, N. A. Hanley, R. O. Oreffo, and F. D. Houghton, "Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions, " Reproduction, vol. 139, no. 1, pp. 85-97, 2009.
62. K. L. Covello, J. Kehler, H. Yu et al., "HIF-2 regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth, " Genes & Development, vol. 20, no. 5, pp. 557-570, 2006.
63. J. Mazumdar, W. T. O'Brien, R. S. Johnson et al., "O2 regulates stem cells through Wnt/-catenin signalling, " Nature Cell Biology, vol. 12, no. 10, pp. 1007-1013, 2010.
64. K. Takubo, N. Goda, W. Yamada et al., "Regulation of the HIF-1alpha level is essential for hematopoietic stem cells, " Cell Stem Cell, vol. 7, no. 3, pp. 391-402, 2010.
65. F. Kocabas, J. Zheng, S. Thet et al., "Meis1 regulates themetabolic phenotype and oxidant defense of hematopoietic stem cells, " Blood, vol. 120, no. 25, pp. 4963-4972, 2012.
66. T. M. Phillips, W. H. McBride, and F. Pajonk, "The response of CD24?//CD44+ breast cancer-initiating cells to radiation, " JNCI Journal of the National Cancer Institute, vol. 98, no. 24, pp. 1777-1785, 2006.
67. M. Diehn, R. W. Cho, N. A. Lobo et al., "Association of reactive oxygen species levels and radioresistance in cancer stem cells, " Nature, vol. 458, no. 7239, pp. 780-783, 2009.
68. O. Herault, K. J. Hope, E. Deneault et al., "A role for GPx3 in activity of normal and leukemia stem cells, " The Journal of Experimental Medicine, vol. 209, no. 5, pp. 895-901, 2012.
69. S. Kim, C. Kwon, and I. Nakano, "Detoxification of oxidative stress in glioma stem cells: mechanism, clinical relevance, and therapeutic development, " Journal ofNeuroscience Research, vol. 92, no. 11, pp. 1419-1424, 2014.
70. T. Ishimoto, O. Nagano, T. Yae et al., "CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth, " Cancer Cell, vol. 19, no. 3, pp. 387-400, 2011.
71. M. Yoshikawa, K. Tsuchihashi, T. Ishimoto et al., "xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma, " Cancer Research, vol. 73, no. 6, pp. 1855-1866, 2013.
72. N. Haraguchi, H. Ishii, K. Mimori et al., "CD13 is a therapeutic target in human liver cancer stem cells, " Journal of Clinical Investigation, vol. 120, no. 9, pp. 3326-3339, 2010.
73. H. M. Kim, N. Haraguchi, H. Ishii et al., "Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon, " Annals of Surgical Oncology, vol. 19, supplement 3, pp. S539-S548, 2012.
74. K. Naka, T. Hoshii, T. Muraguchi et al., "TGF-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia, " Nature, vol. 463, no. 7281, pp. 676-680, 2010.
75. J. Zhou, J. Wulfkuhle, H. Zhang et al., "Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance, " Proceedings of the National Academy of Sciences, vol. 104, no. 41, pp. 16158-16163, 2007.
76. A. Dubrovska, S. Kim, R. J. Salamone et al., "The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 1, pp. 268-273, 2009.
77. H. Yin and J. Glass, "The phenotypic radiation resistance of CS44+/CD24?or low breast cancer cells is mediated through the enhanced activation of ATM signaling, " PLoS ONE, vol. 6, no. 9, Article ID e24080, 2011.
78. T. H. Rushmore and C. Pickett, "Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants, " The Journal of Biological Chemistry, vol. 265, no. 24, pp. 14648-14653, 1990.
79. Y. Li and A. Jaiswal, "Regulation of humanNAD (P)H: quinone oxidoreductase gene. Role of AP1 binding site contained within human antioxidant response element, "The Journal of Biological Chemistry, vol. 267, no. 21, pp. 15097-15104, 1992.
80. T. Prestera, P. Talalay, J. Alam et al., "Parallel induction of heme oxygenase-1 and chemoprotective phase 2 enzymes by electrophiles and antioxidants: regulation by upstreamantioxidantresponsive elements (ARE), "MolecularMedicine, vol. 1, no. 7, p. 827, 1995.
81. K. Itoh, K. Igarashi, N. Hayashi et al., "Cloning andcharacterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins, " Molecular and Cellular Biology, vol. 15, no. 8, pp. 4184-4193, 1995.
82. R. Venugopal and A. K. Jaiswal, "Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene, " Proceedings of the National Academy of Sciences, vol. 93, no. 25, pp. 14960-14965, 1996.
83. K. Itoh, T. Chiba, S. Takahashi et al., "An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements, " Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313-322, 1997.
84. M. Ramos-Gomez, M.-K. Kwak, P. M. Dolan et al., "Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice, " Proceedings of the National Academy of Sciences, vol. 98, no. 6, pp. 3410-3415, 2001.
85. M.-K. Kwak, N. Wakabayashi, K. Itoh, H. Motohashi, M. Yamamoto, and T. W. Kensler, "Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival, "The Journal of Biological Chemistry, vol. 278, no. 10, pp. 8135-8145, 2003.
86. R. Hu, C. Xu, G. Shen et al., "Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (?/?) mice, " Cancer Letters, vol. 243, no. 2, pp. 170-192, 2006.
87. S. Chanas, Q. Jiang, and M. McMahon, "Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice, " Biochemical Journal, vol. 365, no. 2, pp. 405-416, 2002.
88. H.-Y. Cho, S. P. Reddy, A. DeBiase, M. Yamamoto, and S. R. Kleeberger, "Gene expression profiling of NRF2-mediated protection against oxidative injury, " Free Radical Biology and Medicine, vol. 38, no. 3, pp. 325-343, 2005.
89. G. Shen, C. Xu, R. Hu et al., "Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin, " Molecular CancerTherapeutics, vol. 5, no. 1, pp. 39-51, 2006.
90. J. D. Hayes and A. T. Dinkova-Kostova, "The Nrf2 regulatory network provides an interface between redox and intermediary metabolism, " Trends in Biochemical Sciences, vol. 39, no. 4, pp. 199-218, 2014.
91. A. Hayashi, H. Suzuki, K. Itoh, M. Yamamoto, and Y. Sugiyama, "Transcription factor Nrf2 is required for the constitutive and inducible expression ofmultidrug resistance-associated protein 1 in mouse embryo fibroblasts, " Biochemical and Biophysical Research Communications, vol. 310, no. 3, pp. 824-829, 2003.
92. E. Jigorel, M. Le Vee, C. Boursier-Neyret, Y. Parmentier, and O. Fardel, "Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes, " Drug Metabolismand Disposition, vol. 34, no. 10, pp. 1756-1763, 2006.
93. X. Wang, C. R. Campos, J. C. Peart et al., "Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers, " Journal of Neuroscience, vol. 34, no. 25, pp. 8585-8593, 2014.
94. H. Jeong, I. Ryoo, and M. Kwak, "Regulation of the expression of renal drug transporters in KEAP1-knockdown human tubular cells, " Toxicology in Vitro, vol. 29, no. 5, pp. 884-892, 2015.
95. M. J. Canet, M. D. Merrell, B. G. Harder et al., "Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene, " Drug Metabolism and Disposition, vol. 43, no. 1, pp. 93-99, 2014.
96. A. Singh, H. Wu, P. Zhang, C. Happel, J. Ma, and S. Biswal, "Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype, " Molecular Cancer Therapeutics, vol. 9, no. 8, pp. 2365-2376, 2010.
97. N. Wakabayashi, K. Itoh, J. Wakabayashi et al., "Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation, " Nature Genetics, vol. 35, no. 3, pp. 238-245, 2003.
98. S. B. Cullinan, J. D. Gordan, J. Jin, J. W. Harper, and J. A. Diehl, "The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase, "Molecular and Cellular Biology, vol. 24, no. 19, pp. 8477-8486, 2004.
99. D. D. Zhang and M. Hannink, "Distinct cysteine residues in keap1 are required for keap1-dependent ubiquitination of nrf2 and for stabilization of nrf2 by chemopreventive agents and oxidative stress, " Molecular and Cellular Biology, vol. 23, no. 22, pp. 8137-8151, 2003.
100. L. M. Zipper and R. T. Mulcahy, "The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm, " The Journal of Biological Chemistry, vol. 277, no. 39, pp. 36544-36552, 2002.
101. M. C. Jaramillo and D. D. Zhang, "The emerging role of the Nrf2-Keap1 signaling pathway in cancer, " Genes&Development, vol. 27, no. 20, pp. 2179-2191, 2013.
102. K. I. Tong, Y. Katoh, H. Kusunoki, K. Itoh, T. Tanaka, andM. Yamamoto, "Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model, " Molecular and Cellular Biology, vol. 26, no. 8, pp. 2887-2900, 2006.
103. K. I. Tong, A. Kobayashi, F. Katsuoka, andM. Yamamoto, "Twosite substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism, " Biological Chemistry, vol. 387, no. 10-11, pp. 1311-1320, 2006.
104. K. I. Tong, B. Padmanabhan, A. Kobayashi et al., "Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response, " Molecular and Cellular Biology, vol. 27, no. 21, pp. 7511-7521, 2007.
105. M. Kobayashi, L. Li, N. Iwamoto et al., "The antioxidant defense systemKeap1-Nrf2 comprises amultiple sensingmechanism for responding to a wide range of chemical compounds, "Molecular and Cellular Biology, vol. 29, no. 2, pp. 493-502, 2009.
106. T. Yamamoto, T. Suzuki, A. Kobayashi et al., "Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity, " Molecular and Cellular Biology, vol. 28, no. 8, pp. 2758-2770, 2008.
107. M. K. Kwak, K. Itoh, M. Yamamoto, and T. W. Kensler, "Enhanced expression of the transcription factorNrf2 by cancer chemopreventive agents: role of antioxidant response elementlike sequences in the nrf2 promoter, " Molecular and Cellular Biology, vol. 22, no. 9, pp. 2883-2892, 2002.
108. T. Suzuki, T. Shibata, K. Takaya et al., "Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels, "Molecular and Cellular Biology, vol. 33, no. 12, pp. 2402-2412, 2013.
109. S. B. Cullinan, D. Zhang, M. Hannink, E. Arvisais, R. J. Kaufman, and J. A. Diehl, "Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival, " Molecular and Cellular Biology, vol. 23, no. 20, pp. 7198-7209, 2003.
110. W. Li and A. Kong, "Molecular mechanisms of Nrf2-mediated antioxidant response, " Molecular Carcinogenesis, vol. 48, no. 2, pp. 91-104, 2009.
111. Y. J. Surh, "Cancer chemoprevention with dietary phytochemicals, " Nature Reviews Cancer, vol. 3, no. 10, pp. 768-780, 2003.
112. M. Salazar, A. I. Rojo, D. Velasco, R. M. de Sagarra, and A. Cuadrado, "Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2, " Journal of Biological Chemistry, vol. 281, no. 21, pp. 14841-14851, 2006.
113. W. Chen, Z. Sun, X. J. Wang et al., "Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response, " Molecular Cell, vol. 34, no. 6, pp. 663-673, 2009.
114. M. Komatsu, H. Kurokawa, S. Waguri et al., "The selective autophagy substrate p62 activates the stress responsive transcription factorNrf2 through inactivation of Keap1, " Nature Cell Biology, vol. 12, no. 3, pp. 213-223, 2010.
115. J. D. Hayes, M. McMahon, S. Chowdhry, and A. T. Dinkova-Kostova, "Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway, " Antioxidants&Redox Signaling, vol. 13, no. 11, pp. 1713-1748, 2010.
116. R. Hu, C. L. Saw, R. Yu, and A. T. Kong, "Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: Antioxidant coupled with antiinflammatory, " Antioxidants & Redox Signaling, vol. 13, no. 11, pp. 1679-1698, 2010.
117. M. Kwak and T. W. Kensler, "Targeting NRF2 signaling for cancer chemoprevention, " Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 66-76, 2010.
118. K. Iida, K. Itoh, Y. Kumagai et al., "Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis, " Cancer Research, vol. 64, no. 18, pp. 6424-6431, 2004.
119. T. Jiang, N. Chen, F. Zhao et al., "High levels of Nrf2 determine chemoresistance in type II endometrial cancer, " Cancer Research, vol. 70, no. 13, pp. 5486-5496, 2010.
120. Y. R. Kim, J. E. Oh, M. S. Kim et al., "Oncogenic NRF2mutations in squamous cell carcinomas of oesophagus and skin, " The Journal of Pathology, vol. 220, no. 4, pp. 446-451, 2010.
121. T. Shibata, A. Kokubu, M. Gotoh et al., "Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer, " Gastroenterology, vol. 135, no. 4, pp. 1358. e4-1368. e4, 2008.
122. T. Shibata, T. Ohta, K. I. Tong et al., "Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13568-13573, 2008.
123. A. Singh, V. Misra, R. K. Thimmulappa et al., "Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer, " PLoS Medicine, vol. 3, no. 10, article e420, 2006.
124. R. Wang, J. An, F. Ji, H. Jiao, H. Sun, and D. Zhou, "Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues, " Biochemical and Biophysical Research Communications, vol. 373, no. 1, pp. 151-154, 2008.
125. P. Zhang, A. Singh, S. Yegnasubramanian et al., "Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth, "Molecular CancerTherapeutics, vol. 9, no. 2, pp. 336-346, 2010.
126. J. D. Hayes and M. McMahon, "NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer, " Trends in Biochemical Sciences, vol. 34, no. 4, pp. 176-188, 2009.
127. B. Padmanabhan, K. I. Tong, T. Ohta et al., "Structural basis for defects of Keap1 activity provoked by its pointmutations in lung cancer, " Molecular Cell, vol. 21, no. 5, pp. 689-700, 2006.
128. Y. Inami, S. Waguri, A. Sakamoto et al., "Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells, "TheJournal of Cell Biology, vol. 193, no. 2, pp. 275-284, 2011.
129. G. M. DeNicola, F. A. Karreth, T. J. Humpton et al., "Oncogeneinduced Nrf2 transcription promotes ROS detoxification and tumorigenesis, " Nature, vol. 475, no. 7354, pp. 106-109, 2011.
130. L. M. Solis, C. Behrens, W. Dong et al., "Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features, " Clinical Cancer Research, vol. 16, no. 14, pp. 3743-3753, 2010.
131. N. M. Reddy, S. R. Kleeberger, H. Y. Cho et al., "Deficiency in Nrf2-GSH signaling impairs type II cell growth and enhances sensitivity to oxidants, " American Journal of Respiratory Cell and Molecular Biology, vol. 37, no. 1, pp. 3-8, 2007.
132. N. M. Reddy, S. R. Kleeberger, M. Yamamoto et al., "Genetic dissection of the Nrf2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection, " Physiological Genomics, vol. 32, no. 1, pp. 74-81, 2007.
133. Y. Mitsuishi, K. Taguchi, Y. Kawatani et al., "Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming, " Cancer Cell, vol. 22, no. 1, pp. 66-79, 2012.
134. J. Cho, S. Manandhar, H. Lee, H. Park, and M. Kwak, "Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance, " Cancer Letters, vol. 260, no. 1-2, pp. 96-108, 2008.
135. T. Ohta, K. Iijima, M. Miyamoto et al., "Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth, " Cancer Research, vol. 68, no. 5, pp. 1303-1309, 2008.
136. A. Singh, M. Bodas, N. Wakabayashi, F. Bunz, and S. Biswal, "Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance, "Antioxidants&Redox Signaling, vol. 13, no. 11, pp. 1627-1637, 2010.
137. G.-S. Shim, S. Manandhar, D.-H. Shin, T. Kim, and M. Kwak, "Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway, " Free Radical Biology and Medicine, vol. 47, no. 11, pp. 1619-1631, 2009.
138. S. Manandhar, B. Choi, K. Jung et al., "NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity, " Free Radical Biology and Medicine, vol. 52, no. 9, pp. 1773-1785, 2012.
139. T. Kim, E.-g. Hur, S. J. Kang et al., "NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation ofHIF-1, " Cancer Research, vol. 71, no. 6, pp. 2260-2275, 2011.
140. L. Kinch, N. V. Grishin, and J. Brugarolas, "Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FHdeficient papillary renal cell carcinoma type 2, " Cancer Cell, vol. 20, no. 4, pp. 418-420, 2011.
141. J. J. Tsai, J. A. Dudakov, K. Takahashi et al., "Nrf2 regulates haematopoietic stem cell function, " Nature Cell Biology, vol. 15, no. 3, pp. 309-316, 2013.
142. J. H. Kim, R. K. Thimmulappa, V. Kumar et al., "NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation, " The Journal of Clinical Investigation, vol. 124, no. 2, pp. 730-741, 2014.
143. J. P. Chute, "NRF2 mitigates radiation-induced hematopoietic death, " The Journal of Clinical Investigation, vol. 124, no. 3, pp. 960-961, 2014.
144. J. Jang, Y. Wang, H. Kim, M. A. Lalli, and K. S. Kosik, "Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells, " Stem Cells, vol. 32, no. 10, pp. 2616-2625, 2014.
145. S. Murakami, R. Shimizu, P. Romeo, M. Yamamoto, and H. Motohashi, "Keap1-Nrf2 system regulates cell fate determination of hematopoietic stem cells, " Genes to Cells, vol. 19, no. 3, pp. 239-253, 2014.
146. C. E. Hochmuth, B. Biteau, D. Bohmann, andH. Jasper, "Redox regulation by Keap1 and Nrf2 controls intestinal stem cell proliferation in Drosophila, " Cell Stem Cell, vol. 8, no. 2, pp. 188-199, 2011.
147. M. K. Paul, B. Bisht, D. O. Darmawan et al., "Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent notch signaling, " Cell Stem Cell, vol. 15, no. 2, pp. 199-214, 2014.
148. L. Gambari, G. Lisignoli, L. Cattini, C. Manferdini, A. Facchini, and F. Grassi, "Sodium hydrosulfide inhibits the differentiation of osteoclast progenitor cells via NRF2-dependentmechanism, " Pharmacological Research, vol. 87, pp. 99-112, 2014.
149. J. Li, D. Johnson, M. Calkins, L. Wright, C. Svendsen, and J. Johnson, "Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells, " Toxicological Sciences, vol. 83, no. 2, pp. 313-328, 2005.
150. A. A. Merchant, A. Singh, W. Matsui, and S. Biswal, "The redoxsensitive transcription factorNrf2 regulatesmurine hematopoietic stem cell survival independently of ROS levels, " Blood, vol. 118, no. 25, pp. 6572-6579, 2011.
151. N. Gurusamy, D. Ray, I. Lekli, and D. K. Das, "Red wine antioxidant resveratrol-modified cardiac stem cells regenerate infarcted myocardium, " Journal of Cellular and Molecular Medicine, vol. 14, no. 9, pp. 2235-2239, 2010.
152. N. Gorbunov, G. Petrovski, N. Gurusamy, D. Ray, D. H. Kim, and D. K. Das, "Regeneration of infarcted myocardium with resveratrol-modified cardiac stem cells, " Journal of Cellular and Molecular Medicine, vol. 16, no. 1, pp. 174-184, 2012.
153. C. Cai, L. Teng, D. Vu et al., "The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release, " The Journal of Biological Chemistry, vol. 287, no. 40, pp. 33720-33732, 2012.
154. J. Song, S. M. Kang, K. M. Lee, and J. E. Lee, "The protective effect of melatonin on neural stem cell against LPS-induced inflammation, " BioMed Research International, vol. 2015, Article ID 854359, 13 pages, 2015.
155. V. Kärkkäinen, Y. Pomeshchik, E. Savchenko et al., "Nrf2 regulates neurogenesis and protects neural progenitor cells against A toxicity, " STEM CELLS, vol. 32, no. 7, pp. 1904-1916, 2014.
156. M. Mohammadzadeh, R. Halabian, A. Gharehbaghian et al., "Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity, " Cell Stress and Chaperones, vol. 17, no. 5, pp. 553-565, 2012.
157. Y. Takahata, T. Takarada, M. Iemata et al., "Functional expression of 2 adrenergic receptors responsible for protection against oxidative stress through promotion of glutathione synthesis after Nrf2 upregulation in undifferentiated mesenchymal C3H10T1/2 stem cells, " Journal of Cellular Physiology, vol. 218, no. 2, pp. 268-275, 2009.
158. J. Zhu, H. Wang, Y. Fan et al., "Knockdown of nuclear factor erythroid 2-related factor 2 by lentivirus induces differentiation of glioma stem-like cells, " Oncology Reports, vol. 32, no. 3, pp. 1170-1178, 2014.
159. J. Zhu, H. Wang, Q. Sun et al., "Nrf2 is required to maintain the self-renewal of glioma stem cells, " BMC Cancer, vol. 13, no. 1, article 380, 2013.
160. B. L. Emmink, A. Verheem, W. J. Van Houdt et al., "The secretome of colon cancer stem cells contains drug-metabolizing enzymes, " Journal of Proteomics, vol. 91, pp. 84-96, 2013.
161. T. Mizuno, N. Suzuki, H. Makino et al., "Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging systemin reactive oxygen species, " Gynecologic Oncology, vol. 137, no. 2, pp. 299-305, 2015.
162. I.-G. Ryoo, B.-H. Choi, and M.-K. Kwak, "Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells, " Oncotarget, vol. 6, no. 10, pp. 8167-8184, 2015.
163. T. Wu, B. G. Harder, P. K. Wong, J. E. Lang, and D. D. Zhang, "Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy?" Molecular Carcinogenesis, 2014.
164. B. Yang, Y. Ma, and Y. Liu, "Elevated expression of Nrf-2 and ABCG2 involved in multi-drug resistance of lung cancer SP cells, " Drug Research, 2015.
165. M. Zhang, A. Mathur, Y. Zhang et al., "Mithramycin represses basal and cigarette smoke-induced expression of abcg2 and inhibits stem cell signaling in lung and esophageal cancer cells, " Cancer Research, vol. 72, no. 16, pp. 4178-4192, 2012.
166. C. A. Del Vecchio, Y. Feng, E. S. Sokol et al., "De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling, " PLoS Biology, vol. 12, no. 9, Article IDe1001945, 2014.
167. D. Ren, N. F. Villeneuve, T. Jiang et al., "Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1433-1438, 2011.
168. A. Arlt, S. Sebens, S. Krebs et al., "Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity, " Oncogene, vol. 32, no. 40, pp. 4825-4835, 2013.
169. A.-M. Gao, Z.-P. Ke, F. Shi, G. Sun, and H. Chen, "Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway, " Chemico-Biological Interactions, vol. 206, no. 1, pp. 100-108, 2013.
170. A. M. Gao, Z. P. Ke, J. N. Wang, J. Yang, S. Chen, and H. Chen, "Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway, " Carcinogenesis, vol. 34, no. 8, pp. 1806-1814, 2013.